Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 3406 Download: 204 Web of Science: 6 Crossref: 6

Editorial

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis

Takumi Kawaguchi, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):177-180. Published online August 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0246

View: 4808 Download: 178 Web of Science: 3 Crossref: 2

Review

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0310

View: 7752 Download: 374 Web of Science: 58 Crossref: 56

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5108 Download: 335 Web of Science: 7 Crossref: 8

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

View: 5025 Download: 202 Web of Science: 3 Crossref: 3

Review

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0204

View: 8598 Download: 385 Web of Science: 42 Crossref: 40

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5406	MAFLD: How is it different from NAFLD?
Viewed By 5215	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5095	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4727	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Author :

Author index